TFRC and cancer: Specific receptorson cancer cells include transferrin receptors, folate receptors, glycoproteins(e.g., lectin), and epidermal growth factor receptor (EGFR).94 The earliest nanoformulation, approved by theUS FDA in 1995, is the anticancer liposomal formulation Doxil, designedto improve the pharmacokinetics and biodistribution of the anthracyclinedrug doxorubicin.222 Multiple other nanomaterial-basedpharmaceuticals have received approval and have been successfullyused since then for cancer treatment.222,277,278